-
Product Insights
NewHuman Papillomavirus Infections – Drugs In Development, 2024
Empower your strategies with our Human Papillomavirus Infections – Drugs In Development, 2024 report and make more profitable business decisions. Human Papillomavirus (HPV) infections are common sexually transmitted infections caused by the HPV virus. There exist over 100 types, some leading to genital warts, while others increase the risk of various cancers, including cervical, anal, and throat cancers. Often asymptomatic, HPV can spread through sexual contact, including skin-to-skin contact. Vaccines effectively prevent many high-risk HPV types, reducing infection and cancer risk....
-
Product Insights
NewOsteoporosis – Drugs In Development, 2024
Empower your strategies with our Osteoporosis – Drugs In Development, 2024 report and make more profitable business decisions. Osteoporosis, or thinning bones, makes bones weak and more likely to break. Risk factors for osteoporosis include aging, being female, low body weight, low sex hormones or menopause, smoking, and some medications. Signs and symptoms include back pain, caused by a fractured or collapsed vertebra, loss of height over time, a stooped posture, and a bone fracture that occurs much more easily than...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Zanidatamab in Extrahepatic Bile Duct Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Zanidatamab in Extrahepatic Bile Duct Cancer Drug Details: Zanidatamab is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Amylin Agonist Long Acting in Obesity
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Amylin Agonist Long Acting in Obesity report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Amylin Agonist Long Acting in Obesity Drug Details: Amylin...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – QL-415 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - QL-415 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. QL-415 in Solid Tumor Drug Details: QL-415 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Photobac in Gliosarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Photobac in Gliosarcoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Photobac in GliosarcomaDrug Details:Photobac is under development for the treatment of recurrent glioblastoma multiforme,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ATI-2138 in Inflammatory Bowel Disease
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. ATI-2138 in Inflammatory Bowel Disease Drug Details: ATI-2138 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ATI-2138 in Arthritis
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. ATI-2138 in Arthritis Drug Details: ATI-2138 is under development for the treatment of psoriasis, inflammatory...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nifurtimox in Refractory Medulloblastoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Nifurtimox in Refractory MedulloblastomaDrug Details:Nifurtimox is a nitrofuran derivative, acts as an antiprotozoal agent. It is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ATI-2138 in Dermatosis
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. ATI-2138 in Dermatosis Drug Details: ATI-2138 is under development for the treatment of psoriasis, inflammatory...